Biogen and IDEC Pharmaceuticals to Make Presentation at Credit Suisse First Boston Healthcare Conference
November 11 2003 - 6:30PM
PR Newswire (US)
Biogen and IDEC Pharmaceuticals to Make Presentation at Credit
Suisse First Boston Healthcare Conference CAMBRIDGE, Mass., and SAN
DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Biogen, Inc. and IDEC
Pharmaceuticals Corporation announced today that IDEC's Chairman
and Chief Executive Officer, William H. Rastetter, Ph.D., and
Biogen's Chief Financial Officer, Peter Kellogg, will make a
presentation at the Credit Suisse First Boston Healthcare
Conference on Thursday, November 13, 2003 at 9:00 a.m. Mountain
Time (MT) at The Arizona Biltmore Resort in Phoenix, Arizona.
(Logo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Assuming the merger between IDEC and Biogen is approved by
shareholders at Special Meetings on Wednesday, November 12, held in
San Diego and Cambridge, respectively, Mr. Rastetter and Mr.
Kellogg would give a presentation about the new Biogen Idec. The
presentation will be webcast live and is accessible by using the
link provided in the investor relations section of Biogen's
(http://www.biogen.com/) and IDEC's (http://www.idecpharm.com/)
websites. About Biogen Biogen is the world's oldest independent
biotechnology company and a leader in biologics research,
development and manufacturing. A pioneer in leading edge research
in immunology, neurobiology and oncology, Biogen brings novel
therapies to improve patients' lives around the world through its
global marketing capabilities. About IDEC Pharmaceuticals IDEC is a
leader in the discovery, development, and commercialization of
targeted immunotherapies for the treatment of cancer and autoimmune
diseases. IDEC discovered and developed the first commercially
available radioimmunotherapy product (Zevalin(R)) approved in the
United States, which is used to treat certain non-Hodgkin's
lymphomas. IDEC also discovered and, with co-promotion partner
Genentech, Inc., developed the first monoclonal antibody product
(Rituxan(R)) approved in the United States for the treatment of
cancer. Rituxan is approved in over 70 countries worldwide and is
also used to treat various types of non-Hodgkin's lymphomas. IDEC
is a San Diego-based, integrated biopharmaceutical company with
multiple products in clinical stage development and strategic
alliances in a variety of research platforms. Contact: Rob Jacobson
Investor Relations Specialist Biogen, Inc. 617/679-3710
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
http://photoarchive.ap.org/ DATASOURCE: Biogen, Inc. CONTACT: Rob
Jacobson, Investor Relations Specialist of Biogen, +1-617-679-3710
Web site: http://www.biogen.com/ http://www.idecpharm.com/ Company
News On-Call: http://www.prnewswire.com/comp/101550.html
Copyright
Biogen (NASDAQ:BGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Biogen (NASDAQ:BGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024